(MedPage Today) — ORLANDO — Infusions of the investigational monoclonal antibody veligrotug improved symptoms among patients with active and chronic thyroid eye disease, the phase III THRIVE clinical program showed.
By week 15 in 113 patients…
Source link : https://www.medpagetoday.com/meetingcoverage/aace/115658
Author :
Publish date : 2025-05-19 19:34:00
Copyright for syndicated content belongs to the linked Source.
